What Is Small Intestinal Bacterial Overgrowth (SIBO)?

Small intestinal bacterial overgrowth, usually called SIBO, occurs when bacteria that normally live in the colon migrate into or proliferate within the small intestine, where they don’t belong in large numbers. The result is a cluster of digestive symptoms driven by those bacteria fermenting food before your body gets a proper chance to absorb it. What makes SIBO frustrating for patients and clinicians alike is that it sits at the intersection of imperfect diagnostic testing, a long list of associated conditions, and a recurrence rate that keeps many people cycling through treatment.

How the Small Intestine Normally Keeps Bacteria Out

Your gut has several built-in defenses that keep the small intestine relatively low in bacterial count compared to the colon. Stomach acid kills many bacteria before they reach the small bowel. Bile and digestive enzymes create a hostile environment for microbes that do make it through. And perhaps most critically, the migrating motor complex, a wave-like sweeping motion that occurs between meals, physically pushes contents (and bacteria) downstream toward the colon. When any of these defenses weaken, bacteria can accumulate where they shouldn’t.¹

The ileocecal valve, a muscular structure between the small intestine and the colon, also plays a gatekeeping role. In people without SIBO, this valve generates substantially higher pressure when the colon is distended, essentially slamming shut to prevent backflow. In people with SIBO, that pressure response is dramatically weaker. One study found that people with a positive breath test had ileocecal junction pressures roughly half those of people who tested negative, along with slower small bowel transit and higher stomach pH.² A separate study confirmed this pattern, showing that low ileocecal junction pressure was significantly associated with SIBO.³ The takeaway: SIBO isn’t just about having too many bacteria. It’s about losing the barriers that normally keep them in the right place.

Risk Factors and Common Causes

Anything that slows gut motility, reduces stomach acid, or disrupts the anatomy of the gut can increase SIBO risk. The list of associated conditions is strikingly long, spanning irritable bowel syndrome, celiac disease, Crohn’s disease, cirrhosis, diabetes, hypothyroidism, Parkinson’s disease, systemic sclerosis, and many others.⁴ Gastroparesis, where the stomach empties slowly, is another well-known risk factor. The prevailing explanation is that the same delayed transit affecting the stomach also affects the small bowel, giving bacteria more time to settle in and multiply.⁵

Proton pump inhibitors (PPIs), the widely prescribed acid-reducing medications, deserve particular attention. A meta-analysis found that PPI use roughly doubled the odds of developing SIBO, with the association being strongest when SIBO was diagnosed by small bowel aspirate culture rather than breath testing.⁶ One study detected SIBO in half of patients using PPIs, compared to about a quarter of IBS patients and only 6% of healthy controls.⁷ Adding a prokinetic agent (a drug that speeds up gut motility) alongside PPI therapy appeared to lower SIBO rates substantially in one trial.⁸ This doesn’t mean everyone on a PPI will develop SIBO, but it does suggest that long-term acid suppression removes one of the body’s natural bacterial defenses.

Surgical changes to the gut, including gastric bypass and procedures that remove or bypass the ileocecal valve, also set the stage. Any structural change that creates blind loops, strictures, or altered anatomy can produce pockets where bacteria linger and proliferate.

The Post-Infectious Pathway

One of the more compelling recent theories about SIBO involves the immune system’s response to food poisoning. Certain bacteria, particularly Campylobacter jejuni, produce a toxin called cytolethal distending toxin B (CdtB). Researchers have shown in rat models that exposure to this toxin triggers antibodies that don’t just target the toxin itself but also cross-react with vinculin, a protein essential for the normal functioning of the cells that coordinate gut motility.⁹

In follow-up work, rats immunized with CdtB developed elevated anti-vinculin antibodies, reduced vinculin expression in the gut wall, and measurably higher bacterial counts in both the duodenum and ileum.¹⁰ The implication is that a single episode of food poisoning can trigger an autoimmune process that impairs gut motility long after the original infection clears. This would help explain why some people develop chronic SIBO or IBS-like symptoms following gastroenteritis, and why recurrence after antibiotic treatment is so common in these patients: the underlying motility problem hasn’t been fixed.

Symptoms and Nutritional Fallout

The symptom profile of SIBO is maddeningly nonspecific. Bloating, gas, abdominal pain, diarrhea, and sometimes constipation are all common. These are also the symptoms of a dozen other gastrointestinal conditions, which is partly why SIBO can go undiagnosed for years. In children, the same symptoms appear alongside the possibility of stunted growth and malnutrition.¹¹

Beyond discomfort, SIBO can create real nutritional problems. Bacteria in the small intestine compete with your own cells for nutrients. Vitamin B12 deficiency is particularly well documented because anaerobic bacteria consume B12 before it can be absorbed.¹² Fat malabsorption can occur as bacterial enzymes break down bile acids needed for fat digestion, leading to fatty stools and deficiencies in fat-soluble vitamins like A, D, and E. In more severe or long-standing cases, iron deficiency and protein malabsorption can develop.

A more unusual consequence involves a condition called D-lactic acidosis. Certain bacteria, including lactobacillus species, can ferment carbohydrates in the small intestine to produce D-lactic acid. In some patients, this has been linked to a syndrome of “brain fogginess,” confusion, and difficulty concentrating alongside the usual gas and bloating. One clinical report found that this was worsened by heavy probiotic and cultured-yogurt intake, which further colonized the small bowel with lactic-acid-producing bacteria.¹³ This is not the typical scenario, but it underscores that loading up on probiotics without a clear rationale can sometimes backfire.

How SIBO Is Diagnosed

Diagnosis is one of the weakest links in the SIBO story. The traditional gold standard is to collect fluid from the upper small intestine via endoscopy and culture it. Historically, a bacterial count above a certain threshold was considered diagnostic, though in practice, elevated counts showed up across many gastrointestinal conditions, making interpretation tricky.¹⁴ The procedure is also invasive, expensive, and not available in most outpatient settings.

For practical purposes, most clinicians use hydrogen and methane breath tests. You drink a sugar solution (either glucose or lactulose), and your breath is sampled at intervals to detect gases produced by bacterial fermentation. A systematic review with meta-analysis found that the glucose breath test had a pooled sensitivity of about 55% and specificity of about 83%, while the lactulose breath test had a sensitivity of roughly 42% and specificity around 71%.¹⁵ Those numbers mean that breath tests miss a substantial proportion of true cases and can also produce false positives. The lactulose breath test in particular has been questioned as a standalone diagnostic tool in IBS patients.¹⁶

Part of the problem is that there’s no universally accepted definition of what “too many bacteria” actually means. The ESPGHAN Gastroenterology Committee’s recent expert review acknowledged that uncertainty about the exact cut-off has hampered well-designed research on diagnosis and treatment alike.¹⁷ In practice, many clinicians use breath tests as a starting point and combine them with symptom history and clinical context to make a diagnosis.

What Bacteria Are Actually Involved

SIBO is not a single-organism infection. It’s a community shift. The dominant bacteria in the small intestine of people with SIBO are often members of the Proteobacteria phylum, particularly Gammaproteobacteria. One study found that Proteobacteria accounted for about 37% of duodenal bacteria in SIBO patients, roughly three times the proportion seen in controls. The increase was driven largely by families like Enterobacteriaceae, which includes genera such as Klebsiella and Escherichia/Shigella.¹⁸ A separate analysis found enrichment of Clostridium perfringens in the mucosal tissue of people with coliform-type SIBO.¹⁹

Beyond bacteria, there’s growing recognition that methane-producing archaea, particularly Methanobrevibacter smithii, play a distinct role. When these organisms dominate, methane rather than hydrogen rises on breath testing, and the condition is increasingly referred to as intestinal methanogen overgrowth (IMO) rather than SIBO proper.²⁰ Methane appears to slow intestinal transit, which may explain its association with constipation-predominant symptoms. Hydrogen sulfide-producing bacteria, including Fusobacterium and Desulfovibrio species, represent yet another gas pattern. Elevated hydrogen sulfide in the breath has been linked to diarrhea-predominant IBS and a distinct microbial profile.²¹ Measuring hydrogen sulfide is still relatively new, and standardized criteria for diagnosing hydrogen sulfide SIBO remain in development.²²

The IBS Overlap

SIBO and irritable bowel syndrome share so many symptoms that the relationship between them has been debated for years. One cohort study found SIBO in about 36% of IBS patients, with methane-positive results being roughly three times more common than hydrogen-positive results in that group.²³ Interestingly, the severity of IBS symptoms as measured by validated scoring tools did not correlate with total gas production, suggesting that having more bacteria does not necessarily mean worse symptoms.

The gas patterns did line up with symptom type, though. Methane production was significantly higher in constipation-predominant IBS, while hydrogen production was higher in diarrhea-predominant IBS.²⁴ This is consistent with the broader understanding that methane slows transit while hydrogen (and hydrogen sulfide) may accelerate it. For people with IBS who have not responded to standard treatments, testing for SIBO can sometimes reveal a treatable underlying component, though it clearly doesn’t explain every case.

Antibiotic Treatment

Rifaximin, a poorly absorbed antibiotic that stays mostly in the gut, is the most studied treatment for SIBO. A meta-analysis found an overall eradication rate of about 71% based on intention-to-treat analysis, with an adverse event rate under 5%.²⁵ An earlier trial using 800 mg per day for four weeks reported that rifaximin normalized glucose breath tests in about half of patients and was most effective when diarrhea was the dominant symptom.²⁶

Rifaximin’s main limitation is cost, especially in health systems where it isn’t covered by insurance for a SIBO indication. It also tends to work better for hydrogen-dominant SIBO than for methane-dominant cases; clinicians often add a second antibiotic (neomycin or metronidazole) when targeting methanogens. Recurrence is the other major issue. Because antibiotics don’t address the structural or motility defects that allowed bacteria to accumulate in the first place, SIBO frequently returns after a successful course of treatment. This is where prokinetics and dietary strategies come into the picture as maintenance tools.

Herbal Alternatives and the Probiotic Question

For patients who don’t respond to rifaximin or prefer to avoid repeated antibiotic courses, herbal antimicrobials have shown promise. In a retrospective study, a combination herbal protocol normalized lactulose breath tests in 46% of patients, compared to 34% for rifaximin, though the difference was not statistically significant. Among rifaximin non-responders who were then given herbal rescue therapy, about 57% achieved a negative breath test, a response rate comparable to triple antibiotic rescue.²⁷ The herbs used in these protocols typically include combinations like oregano oil, berberine-containing plants, and other botanical antimicrobials, though standardized formulations vary across practitioners.

Probiotics occupy a murkier space. A systematic review and meta-analysis found that probiotic supplementation significantly improved the rate of bacterial decontamination (about 63% in the probiotic group), reduced breath hydrogen levels, and decreased abdominal pain scores. However, probiotics did not prevent SIBO from developing in the first place and did not reduce stool frequency.²⁸ Combining antibiotics with probiotics may improve outcomes, particularly in vulnerable groups such as children.²⁹ But as noted earlier, excessive or indiscriminate probiotic use can sometimes worsen symptoms by further colonizing the small intestine, so a blanket recommendation to “take probiotics” oversimplifies a situation that depends on the individual’s microbial landscape.

Diet, Prokinetics, and Preventing Recurrence

Dietary modification is widely used alongside antibiotic treatment, though the evidence base is thinner than many patients expect. Low-fermentation diets, including the low-FODMAP approach, aim to starve the overgrown bacteria by limiting the carbohydrates they ferment. These diets can be effective at reducing symptoms, but they are restrictive and not intended for long-term use. A narrative review noted that dietary interventions for SIBO remain “variably applied, with heterogeneous outcomes across studies,” which is a diplomatic way of saying the field hasn’t reached consensus on what to eat.³⁰

Prokinetic agents, which enhance the migrating motor complex, are often used after antibiotic treatment to help prevent relapse. The logic is straightforward: if impaired motility allowed the bacteria to accumulate, restoring that motility should help keep them from coming back. Low-dose erythromycin (used for its prokinetic rather than antibiotic effect), prucalopride, and low-dose naltrexone are among the options clinicians consider, though large trials specifically in SIBO prevention are limited. Meal spacing is another practical strategy; the migrating motor complex activates during fasting periods, so grazing all day can suppress the very mechanism that sweeps bacteria downstream.

SIBO in Children

SIBO in children deserves separate consideration because the presentation, consequences, and diagnostic challenges differ from adults. Children with SIBO often present with chronic abdominal pain, bloating, diarrhea, and flatulence, but the condition has also been implicated in stunting, which affects millions of children worldwide.³¹ The nutritional impact can be more severe than in adults because children’s growth and development depend on reliable nutrient absorption during critical windows.

Diagnosis in children faces the same limitations as in adults, perhaps magnified. Breath testing requires a cooperative child who can follow the fasting protocol and provide reliable samples over an extended period. The carbohydrate breath test is considered safe and noninvasive, but a standardized methodology for pediatric use is still lacking.³² Pediatric risk factors overlap with adult ones but also include conditions more common in childhood, such as cystic fibrosis, short bowel syndrome from neonatal surgery, and anatomical anomalies. Treatment generally follows the same principles as in adults, with antibiotics as the mainstay and probiotics as a potential adjunct, though the evidence in children specifically remains limited.